Ark. High Court Overturns J&J's $1.2B Risperdal Fine

Law360, New York (March 20, 2014, 4:11 PM EDT) -- Johnson & Johnson and a subsidiary on Thursday dodged a more than $1.2 billion fine over their marketing of the antipsychotic drug Risperdal when the Arkansas Supreme Court found that the state wrongly sued the pharmaceutical giant under a law targeting health care facilities.

The state’s highest court dismissed the state’s claim under the Arkansas Medicaid Fraud False Claims Act, saying that law is meant only for health care facilities. Arkansas Attorney General Dustin McDaniel had accused J&J and its unit Janssen Pharmaceuticals Inc. of violating...
To view the full article, register now.